• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

靶向治疗：治疗晚期肾癌——任重道远。

Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.

机构信息

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, MD 20892, USA.

出版信息

Nat Rev Clin Oncol. 2013 Nov;10(11):614-5. doi: 10.1038/nrclinonc.2013.183. Epub 2013 Oct 15.

DOI:10.1038/nrclinonc.2013.183
PMID:24129349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4174460/
Abstract

A randomized phase III trial comparing pazopanib with sunitinib in patients with advanced clear cell renal cell carcinoma showed that although progression-free survival and overall survival were similar, pazopanib was better tolerated. Recent advances in genomics and metabolomics have provided novel insights that could be leveraged to improve therapy.

摘要

一项比较帕唑帕尼与舒尼替尼治疗晚期透明细胞肾细胞癌患者的随机 III 期临床试验表明，虽然无进展生存期和总生存期相似，但帕唑帕尼的耐受性更好。基因组学和代谢组学的最新进展提供了新的见解，这些见解可以被利用来改善治疗。

相似文献

1
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.靶向治疗：治疗晚期肾癌——任重道远。
Nat Rev Clin Oncol. 2013 Nov;10(11):614-5. doi: 10.1038/nrclinonc.2013.183. Epub 2013 Oct 15.
2
[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].[帕唑帕尼治疗转移性肾癌患者进展后的靶向治疗的另一种方法：捷克转移性肾癌合作组的专家评估]
Klin Onkol. 2013;26(1):55-7.
3
Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.帕唑帕尼治疗转移性肾细胞癌长期存活男性的病例报告。
Tumori. 2014 Mar-Apr;100(2):e59-62. doi: 10.1177/030089161410000227.
4
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.帕唑帕尼治疗复发性肾细胞癌患者出现葡萄膜转移和重症肌无力。
Clin Genitourin Cancer. 2014 Aug;12(4):e143-6. doi: 10.1016/j.clgc.2014.02.002. Epub 2014 Feb 21.
5
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.转移性肾细胞癌中的“权力的游戏”：血管内皮生长因子酪氨酸激酶抑制剂与雷帕霉素靶蛋白抑制剂的地位之争
Clin Genitourin Cancer. 2013 Mar;11(1):1-4. doi: 10.1016/j.clgc.2012.11.006. Epub 2012 Dec 29.
6
Pazopanib for the treatment of renal cell carcinoma.帕唑帕尼用于治疗肾细胞癌。
Future Oncol. 2015;11(8):1169-79. doi: 10.2217/fon.14.274.
7
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.一线使用帕唑帕尼治疗，随后使用血管内皮生长因子受体酪氨酸激酶抑制剂或雷帕霉素靶蛋白抑制剂治疗的未经选择的转移性透明细胞肾细胞癌患者的结局：单机构经验
BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.
8
Pazopanib.帕唑帕尼。
Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073.
9
Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.帕唑帕尼成功治疗肾细胞癌心脏转移：酪氨酸激酶抑制剂抗血管生成活性的影响
Tumori. 2014 Nov-Dec;100(6):e298-300. doi: 10.1700/1778.19304.
10
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].[匈牙利首次使用帕唑帕尼治疗转移性肾癌患者的经验]
Magy Onkol. 2013 Sep;57(3):173-6. Epub 2013 Aug 9.

引用本文的文献

1
Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.肾肿瘤的生物标志物：现状与临床前景
Curr Urol Rep. 2017 Jan;18(1):3. doi: 10.1007/s11934-017-0655-1.
2
Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.中尺度纳米颗粒选择性靶向肾近端小管上皮。
Nano Lett. 2015 Apr 8;15(4):2358-64. doi: 10.1021/nl504610d. Epub 2015 Mar 26.

本文引用的文献

1
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
2
Integrated molecular analysis of clear-cell renal cell carcinoma.透明细胞肾细胞癌的综合分子分析。
Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24.
3
Comprehensive molecular characterization of clear cell renal cell carcinoma.透明细胞肾细胞癌的全面分子特征分析。
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23.
4
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.3p21 组蛋白修饰基因 BAP1 和 SETD2 突变的肾透明细胞癌不良预后：来自 MSKCC 和 KIRC TCGA 研究网络的报告。
Clin Cancer Res. 2013 Jun 15;19(12):3259-67. doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25.
5
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.IDH1 介导的还原性谷氨酰胺代谢在低氧条件下促进脂肪生成。
Nature. 2011 Nov 20;481(7381):380-4. doi: 10.1038/nature10602.
6
Reductive carboxylation supports growth in tumour cells with defective mitochondria.还原羧化作用为线粒体功能缺陷的肿瘤细胞生长提供支持。
Nature. 2011 Nov 20;481(7381):385-8. doi: 10.1038/nature10642.
7
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.外显子组测序鉴定出肾癌中 SWI/SNF 复合物基因 PBRM1 的高频突变。
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
8
The genetic basis of kidney cancer: a metabolic disease.肾癌的遗传基础：一种代谢疾病。
Nat Rev Urol. 2010 May;7(5):277-85. doi: 10.1038/nrurol.2010.47.
9
Molecular diagnosis and therapy of kidney cancer.肾肿瘤的分子诊断与治疗。
Annu Rev Med. 2010;61:329-43. doi: 10.1146/annurev.med.042808.171650.
10
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.系统测序肾细胞癌揭示组蛋白修饰基因失活。
Nature. 2010 Jan 21;463(7279):360-3. doi: 10.1038/nature08672. Epub 2010 Jan 6.